Epilepsy Therapeutics Market Strategies and Forecast 2019

Epilepsy Therapeutics Market Size, Share, Global Trends, Company Profiles,

Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation

and Forecast To 2019

In 2012, the overall industry for epilepsy therapeutics in the major developed markets

contributed for an approximate share of over $3.1 billion. Furthermore, this market is

anticipated to expand at a total CAGR of over 3.3% to cross over $4.2 billion over the forecast

period till 2019.

Epilepsy is described by recurring seizures as it is a set of long-term neurological disorders.

When a group of neurons in brains or nerve cells send wrong signals, episodes of these seizures

occur. Depending on the cause of the epilepsy, seizures may possibly be different from primary

comprehensive seizures to partial seizures. Patients suffering from epilepsy act weirdly and

grumble about strange sensations and emotions. People of all ages are being affected by epilepsy

as it is the fourth most common disorder. Doctors prescribe drugs or antiepileptic medicines for

the treatment of epilepsy. It depends on the age of the patient seriousness of the seizures and type

of seizures to be treated

Recent approvals of drugs coupled with novel technologies of action are some of the factors

attributing to the industry growth of the market. The U.S region contributes to the major market

share for over 55% for the total market. In addition, three new anti-epileptic drugs have been

permitted in the aforementioned region since 2012. Fycompa, Trobalt and Aptiom are also

projected to be launched over the coming years. Moreover, brivaracetam is likely to approve

over the coming years. Factors such as improved safety and tolerability of fycoma and trobalt

are also contributing significantly owing to the increased interest of prescribers over the past few

years.

Access Full Report:...